Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.46EUR
15 Dec 2017
Change (% chg)

€-0.01 (-1.67%)
Prev Close
€0.47
Open
€0.47
Day's High
€0.48
Day's Low
€0.46
Volume
7,819,835
Avg. Vol
4,288,811
52-wk High
€0.54
52-wk Low
€0.40

Chart for

About

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company’s activities include identification and development of bio-pharmaceuticals reducing the tumor mass... (more)

Overall

Beta: 0.99
Market Cap(Mil.): €184.88
Shares Outstanding(Mil.): 444.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Molmed: Italian Medicines Agency Sets Price Of Reimbursement For Zalmoxis

* ITALIAN MEDICINES AGENCY SETS GROSS PRICE OF REIMBURSEMENT FOR ZALMOXIS AT EUR 149,000 PER INFUSION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

13 Dec 2017

BRIEF-Molmed submits utilization request for third tranche of share capital increase

* SUBMITTED UTILIZATION REQUEST FOR THIRD TRANCHE OF SHARE CAPITAL INCREASE TO BE RESERVED TO SOCIETE GENERALE AS PER SEF AGREEMENT

21 Sep 2017

BRIEF-Molmed completes second tranche of share capital increase reserved to Societe Generale

* SECOND TRANCHE OF SHARE CAPITAL INCREASE RESERVED TO SOCIETE GENERALE PURSUANT TO “SEF - STANDBY EQUITY FACILITY” AGREEMENT COMPLETED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Aug 2017

BRIEF-Molmed H1 net loss shrinks to EUR 6.5 million

* REPORTED ON THURSDAY H1 OPERATING REVENUE EUR 9.8 MILLION VERSUS 10.2 MILLION A YEAR AGO

28 Jul 2017

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

27 Jul 2017

BRIEF-Molmed signs strategic commercialization and supply agreements with Dompe

* MOLMED AND DOMPE SIGN 15-YEAR LICENSE AND DISTRIBUTION AGREEMENT FOR SUPPLY OF ZALMOXIS IN EUROPE

26 Jul 2017

BRIEF-Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories

* MOLMED AND TTY BIOPHARM ENTER INTO AN EXCLUSIVE AGREEMENT TO COMMERCIALISE ZALMOXIS® IN CERTAIN ASIAN TERRITORIES

30 Jun 2017

Earnings vs. Estimates